Introduction
As therapeutic proteins become more complex there is an opportunity to consider approaches that utilize site-specific conjugation technologies to link proteins that are easily made. Such a hybrid recombinant-chemical approach could in principle be used in a modular way to make a wide range of multifunctional proteins that would not be practical and cost-effective to make by recombinant technologies alone, especially in the early stage of development. An exclusively recombinant approach to make multifunctional therapeutic proteins requires that a polypeptide sequence must be used to link the two or more proteins together. As a non-natural sequence, the linking region may be immunogenic, so polypeptide linkers must be both functional and non-antigenic. As proteins become more complex, there is also often an increased propensity for aggregation and degradation during manufacture and storage [1] [2] .
Many proteins are structurally and functionally complex and form dimers 3 .
Interferon (IFN) is a cytokine that was first described as an antiviral agent 4 . Type 1
IFNs act on a target cell (not the virus) to inhibit replication and the lifecycle of a wide variety of viruses, thus conferring a state of resistance within the cell to viral infection 5 . There are a number of pharmaceutical forms of Type I IFNs, namely Infergen ® , Intron A ® , PegIntron ® and Pegasys ® for the treatment of viral diseases such as Hepatitis B and Hepatitis C 6 . IFN α-2b in the presence of zinc forms dimers that have been found to have similar crystal structures to interleukin-10 and IFN-γ, which interact with their receptors in the dimer form [7] [8] .
Site-specific protein modification technologies are required to link proteins together in a hybrid recombinant-chemical approach [9] [10] [11] [12] to make multifunctional proteins. There may be many therapeutic opportunities for multifunctional proteins 2, [13] [14] [15] . Proteins linked together to be multivalent (for example, 16 ) or dimeric [17] [18] [19] have been described using a range of modification technologies. Dimerised proteins may increase avidity while also increasing solution size to prolong circulation times 12, 20 .
Recombinant 21 and chemical [22] [23] methods have been used to make different cytokine dimers 2 .
Disulfide re-bridging conjugation is a site-specific method for protein modification that exploits the reactivity of the two thiols found in a native disulfide ( Figure 1A ) [24] [25] . Mechanistically conjugation occurs by bis-alkylation by a sequence of addition-elimination reactions ( Figure 1B ). Interferon α2 has two disulfides, either of which can be readily conjugated ( Figure 2 ).
FIGURES 1-2
Disulfide re-bridging conjugation has also been used with reagents functionalized at each terminus of a PEG linker (e.g. PEG di(bis-sulfone) 4, Figure   3B ) to make bivalent IgG antibody mimetics called Fab-PEG-Fab (FpFs) 26 . FpFs are about the same size in solution as an IgG and can be made to be more stable in the hinge region. FpFs have been shown to be biologically active in vitro and in vivo with binding affinities comparable to IgGs targeted to the same epitopes 27 . Interestingly, FpFs display a propensity to have slower dissociation rates once bound to their target. Exploiting reduced dissociation rates may be a strategy to increase efficacy by retaining a therapeutic agent for a longer period of time within a target tissue [28] [29] .
Fc-fusion mimetics known as receptor-PEG-receptor (RpR) have also been prepared 30 . It was found that for an RpR targeted to vascular endothelial growth factor, that the RpR displayed a higher rate of association as well as a slower rate of disassociation. Together, these properties showed that a recombinant-chemical fusion protein mimetic can have higher affinity than a recombinant protein targeting the same epitope.
IFN binds to two cell surface receptors that then dimerise, so much of the solvent accessible surface of IFN is involved in binding 31 . Histidines are generally rare in proteins and contiguous histidines are only generally present in His-tags, which are widely used to simplify protein purification. In an effort to avoid modifying the IFN near a residue that may be involved in binding, IFN was made with an 8-Histidine tag (His 8 -tag) at its N-terminus and then site-specifically mono-and diPEGylated by bis-alkylation using the PEG mono-sulfone 3 ( Figure 3C ) 32 . His-tag conjugation is thought to occur by a similar addition-elimination reaction ( Figure 3D) that occurs with the two thiols from a disulfide bond.
Following a recombinant-chemical approach to make IFN-α2 homo-dimers, activity of the IFN homo-dimer was determined. The cytokine was prepared recombinantly with an His 8 -tag at its N-terminal (His 8 IFN). PEG-di(mono-sulfone) 5 ( Figure 3B ) was then used to make an IFN homo-dimer by histidine-specific conjugation (His 8 IFN-PEG-His 8 IFN). His 8 IFN was also used to make IFN-PEG-IFN by disulfide re-bridging conjugation using PEG di(bis)sulfone 4. Disulfide conjugation on His 8 IFN had not been conducted before this study. Mono-PEGylated and diPEGylated conjugates were also prepared as controls for comparison. PEG steric shielding should be at a maximum in the diPEGylated species ( Figure 2 ) and the extent of PEG shielding was probed using a low molecular weight PEG (5 kDa) to make mono-and di-PEGylated IFN conjugates by disulfide re-bridging conjugation.
Materials and methods

Preparation of PEG conjugation reagents
PEG bis-sulfone reagents 1 were prepared as previously described 25 using commercially available methoxy-terminated PEG mono-amine precursors of 5, 10
and 20 kDa molecular weights. The PEG di-(bis-sulfone) reagents were prepared as previously described 26 and further purified by HPLC. Incubation of the PEG bissulfone precursors (1 and 4) for 8 h (37°C) in 50 mM sodium phosphate buffer pH 7.4
containing 150 mM sodium chloride provided PEG mono-sulfone 3 and PEG di-(mono-sulfone) 5 for histidine-specific conjugation.
His 8 IFN production
The IFN α-2a (IFN) gene was designed to include eight histidines (His 8 ) at the Nterminus 32 . The DNA sequence was optimized using Gene Perfect software (Gene Oracle, Mountain View, California) and further optimized by manual removal of rare codons and repetitive sequences to remove double-strand RNA secondary structure. were also prepared with yields of 29% and 34.5%, respectively. and then incubated with sodium triacetoxyborohydride (100 mM) dissolved in DMSO at 4ºC for 1.5 h. The crude mixture was then buffer exchanged into 100 mM sodium acetate, pH 4.0, using a pre-equilibrated PD-10 desalting column. The reaction mixture was then loaded into a 5 mL HiTrap Macrocap SP CIEC column using an ÄKTA prime plus fitted with a 5 mL loop which had been pre-equilibrated with buffer was measured by UV at 280 nm and MicroBCA assay.
Preparation of PEG
Preparation of IFN dimer, IFN-PEG-IFN by disulfide re-bridging conjugation
His 8 IFN (2 mg/mL, 5 mL) in 50 mM sodium phosphate 20 mM EDTA, pH 7.8, was reduced using DTT (1 M, 15.4 mg, 125 µL) for 30 min at RT, and the DTT was removed by buffer exchange using three pre-equilibrated PD-10 columns. Protein concentration was quantified by UV at 280 nm (0.752 mg/mL, 11 mL) and His 8 IFN was diluted to 0.5 mg/mL (15 mL), where one half (7.5 mL, 4.1 mg) of this reduced GSH:50 mM GSSG in 50 mM sodium acetate, pH 4.0) was added, and the reaction was allowed to proceed for a further 16 h at 20ºC. SDS-PAGE analysis was conducted on the reaction mixture prior to and after GRS addition. The IFN-PEG 20 -IFN conjugate was then incubated with sodium triacetoxyborohydride (100 mM dissolved in DMSO) at 4ºC for 1.5 h. The reaction mixture (7.5 mL) was then buffer exchanged into 100 mM sodium acetate, pH 4.0, using three pre-equilibrated PD-10 desalting columns. CIEC purification was conducted with a 5 mL Macrocap SP ion exchange column using an ÄKTA Prime Plus fitted with two 5 mL loops which had been pre-equilibrated with buffer A (100 mM sodium acetate, pH 4.0). 
Assessment of conjugate stability
Samples were incubated at 4ºC for 7 days and monitored by SDS-PAGE with the resulting gels stained by InstantBlue™ and PEG stain. For conjugated proteins with a low concentration, silver stain was used to detect the conjugate and any free protein.
Accelerated stability assessments were conducted by first buffer exchanging samples into 10 mM ammonium bicarbonate, pH 8.0, and protein concentrations were diluted to 50 µg/mL, and then 27 µL was transferred into 4×0. 
Antiviral potency assay
The human lung fibroblast A549 cell line (HPACC; 86012804) was maintained in The interferon concentration (the log reciprocal of the interferon dilution) was plotted against the absorbance achieved and the reduction in cell viability was fitted to a sigmoidal dose-response curve. Data was only considered valid under two criteria, i) the variation between the straight part of the sigmoidal curve and the data points was small enough to be accurately represented by a straight line (absolute sum of squares (r value)) and ii) the ED 50 for the internal control, NIBSC IFN α, was within the expected range. If the data achieved was not in line with this criterion, the data were not used. Accepted potency data was then turned into international units (IU) to allow for direct comparisons to be made with data described in the literature.
GraphPad Prism 5 was used for all data analysis.
Antiproliferative assay
The mg/mL, Sigma) was dissolved in PBS and was prepared 10 min before addition to the wells. MTT solution was filtered through a 0.2 µm syringe filter and then added (20 µL) to each well and the plates incubated for 3 h at 37ºC, 5% CO 2 . Plates were then centrifuged at 1500×g for 10 min, allowing formazan crystals to sediment. Using a multichannel pipette, the supernatant was carefully removed and 100 µL/well nonsterile DMSO was added to solubilize the crystals by agitation. Absorbance was then measured at 570 nm. Cell viability (%) was plotted against control wells using sitespecific binding with Hill slope on a semi-log graph (GraphPad Prism 5). The interferon concentration (the log reciprocal of the interferon dilution) was plotted against the absorbance achieved and the reduction in cell viability was fitted to a sigmoidal dose-response curve. Data was only accepted if the variation between the straight part of the sigmoidal curve and the data points was small enough to be accurately represented by a straight line (absolute sum of squares (r value)).
Results and Discussion
Reagent synthesis.
Terminally functionalized PEG di(bis-sulfones) 4 ( Figure 3B ) capable of bis-alkylation conjugation at each PEG terminus were prepared using commercially available 10 and 20 kDa PEG diamines (NH 2 -PEG-NH 2 ) 26 and the precursor bis-sulfone linker 25 .
Likewise the, PEG bis-sulfones 1 were prepared from commercially available 5, 10 and 20 kDa PEG amine 25 . The mono-sulfone adducts (3 and 5) were obtained by elimination of toluene sulfinic acid 2 24 .
FIGURE 3
Preparation of His 8 IFN
Recombinant IFN α-2a fused with an eight-histidine tag (His 8 ) was prepared by using the SHuffle™ T7 expression system which can correctly produce disulfide containing proteins in high yields within the cytoplasm of E. coli 33 
FIGURE 5
The conjugation was repeated and a single CIEX purification was conducted Table 1 ).
TABLE 1
The purified His 8 IFN-PEG 20 -His 8 IFN was stored at 4°C for 2 months (50 mM sodium phosphate containing 150 mM sodium chloride, pH 7. Figure 5D ). No de-conjugation was observed for either of these conjugates.
Preparation of IFN-PEG-IFN homo-dimers by disulfide re-bridging conjugation
Conjugation of the disulfide thiols has not previously been conducted on His 8 IFN.
Once the IFN thiols are liberated after disulfide reduction, thiol addition to the PEG bis-sulfone reagents (1 and 4) is much more favored compared to the addition reaction of the imidazole side-chain of histidine. IFN has two accessible disulfides and IFN maintains its tertiary structure in the presence of DTT after reduction of the disulfides 35 .
Bis-alkylation conjugation of His 8 IFN was first conducted using PEG bissulfone 1 (5, 10 and 20 kDa) to prepare the corresponding PEG-IFN and PEG 2 -IFN conjugates ( Figure 6A , lanes 3-8, Table 1 ). These conjugates were isolated from the same reaction mixture using 1 molar equivalent of PEG bis-sulfone 1 to protein, and the PEG 2 -IFN conjugate was easily isolated as a co-product. The conjugation conversion and the purification process comprising a single CIEX for the His 8 IFNderived conjugates is similar to what has been observed with IFN 36 that does not possess a His-tag.
FIGURE 6
The IFN-PEG-IFN homo-dimers were prepared using a 2:1 molar ratio of Table 1), suggesting there could be a dependency on PEG size linking the two IFNs.
FIGURE 7
The histidine-specific mono-PEGylated conjugate (PEG 20 Due to the site specificity of the disulfide re-bridging PEGylation, the activity of PEG 10 -IFN and PEG 20 -IFN were comparable as previously reported 24 .
Interestingly, the PEG 5 -IFN conjugate displayed considerably more activity than any of the higher molecular weight PEG-IFN conjugates ( Figure 7 and Table 1 ),
suggesting that when PEG 5 is site-specifically conjugated by disulfide re-bridging conjugation, this molecular weight of PEG is below a steric shielding threshold at these sites of conjugation.
An antiproliferative assay using Daudi cells was conducted, but due to the large quantity of sample required, only the disulfide re-bridged mono-PEGylated and IFN homo-dimers were evaluated. As with the antiviral assay, the PEG 10 homo-dimer 
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Figures
Figure 1 Reagents that are functionalized at each PEG terminus can be used to prepare IFN homodimers (IFN-PEG-IFN). IFN can also be prepared with a His-tag (His 8 in this study) at the Nterminus which can be site-specifically conjugated with the same reagents used for disulfide re-bridging conjugation. Table 1 . Summary of purification, yield and specific activities achieved for the IFN-PEG-IFN homo-dimers (in red) and the controls that were prepared. Grey shading used to indicate the His 8 -tag conjugated species that were prepared. The remaining conjugates were prepared by disulfide re-bridging conjugation.
